| Identification | More | [Name]
Diclofenac diethylamine | [CAS]
78213-16-8 | [Synonyms]
2-[(2,6-dichlorophenyl)amino]-benzeneacetic acid compd. with n-ethylethanamine (1:1)
DICLOFENAC DIETHYLAMINE
n-ethylethanamine 2-[(2,6-dichlorophenyl)amino]benzeneacetate
2-[(2,6-dichlorophenyl)amino]-benzeneacetic acid compd. with n-ethylethanamine | [EINECS(EC#)]
616-599-2 | [Molecular Formula]
C18H22Cl2N2O2 | [MDL Number]
MFCD01862249 | [Molecular Weight]
369.29 | [MOL File]
78213-16-8.mol |
| Chemical Properties | Back Directory | [Melting point ]
145-148°C | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
DMF: 30 mg/ml; DMSO: 10 mg/ml; Ethanol: 30 mg/ml; PBS (pH 7.2): 2 mg/ml | [form ]
A crystalline solid | [color ]
White to off-white | [Stability:]
Hygroscopic | [Major Application]
pharmaceutical
pharmaceutical small molecule | [InChI]
InChI=1S/C14H11Cl2NO2.C4H11N/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;1-3-5-4-2/h1-7,17H,8H2,(H,18,19);5H,3-4H2,1-2H3 | [InChIKey]
ZQVZPANTCLRASL-UHFFFAOYSA-N | [SMILES]
C1(=CC=CC=C1CC(=O)O)NC1C(Cl)=CC=CC=1Cl.N(CC)CC | [CAS DataBase Reference]
78213-16-8(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Uses]
Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug taken to reduce inflammation and as an analgesic reducing pain in certain conditions. | [in vivo]
Diclofenac (3 mg/kg, b.i.d., for 5 days) significantly increases faecal 51Cr excretion in rats, and such effect is also observed in squirrel monkeys after administrated of 1 mg/kg twice daily for 4 days[1].
Diclofenac (10 mg/kg; administered via oral route just prior to induction of inflammation) shows in vivo anti-inflammatory activity in Wistar rats[1]. | Animal Model: | Male Sprague-Dawley rats (150±200 g)[1] | | Dosage: | 3 mg/kg | | Administration: | Oral administration, b.i.d., for 5 days | | Result: | Resulted in a significant increase in faecal 51Cr excretion. |
| Animal Model: | Wistar rats (150-175 g) bearing Formalin-induced rat foot paw edema model[2] | | Dosage: | 10 mg/kg | | Administration: | Administered via oral route just prior to induction of inflammation | | Result: | Showed in vivo anti-inflammatory activity (% edema inhibition=29.2, 1 h; 22.2, 3 h; 20, 6 h). |
| [IC 50]
Human COX-2: 1.3 nM (IC50, in CHO cells); Human COX-1: 4 nM (IC50, in CHO cells); Ovine COX-2: 0.84 μM (IC50); Ovine COX-1: 5.1 μM (IC50) |
|
|